Paid ALS (Amyotrophic Lateral Sclerosis) Clinical Trials
ALS clinical trials seeking participants. Compensation provided for qualifying individuals. Access investigational therapies. Comprehensive care from specialized neurologists.
Compensation
$2,500 - $5,000
Duration
48-72 weeks
Phase
Phase II
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-75 years
- Diagnosis of definite or probable ALS per El Escorial criteria
- Symptom onset within the past 36 months
- Slow Vital Capacity (SVC) ≥ 50% of predicted
- Able to swallow tablets or receive study drug via feeding tube
- Caregiver available to assist with study procedures
Who May Not Qualify
- Tracheostomy or invasive ventilation
- Other neurodegenerative diseases
- Participation in another interventional study within 30 days
- Significant cognitive impairment
Frequently Asked Questions
What treatments are being investigated for ALS?
+
Current ALS studies are exploring various approaches including gene therapies, neuroprotective agents, stem cell treatments, and drugs targeting specific disease mechanisms. These investigational treatments aim to slow disease progression and improve quality of life.
Can I continue taking Riluzole or Edaravone?
+
Most studies allow participants to continue FDA-approved ALS treatments like Riluzole or Edaravone. The study team will review your current medications during the screening process.
What support is provided for travel to study visits?
+
Many ALS studies offer travel assistance, including reimbursement for mileage, parking, and accommodations if needed. Some studies also provide home nursing visits to reduce the burden of travel.
How is my safety monitored during the study?
+
Your safety is continuously monitored through regular assessments, blood tests, and neurological examinations. An independent Data Safety Monitoring Board reviews safety data throughout the study.